Patents by Inventor Simon James Watson

Simon James Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-malarial antibodies that bind circumsporozoite protein
    Patent number: 11066464
    Abstract: Antibodies that bind to the circumsporozoite protein (CSP) of Plasmodium falciparum. Use of such antibodies as anti-malarial agents, to confer protection against infection by malarial parasites such as P. falciparum by insect vector transmission. Diagnosis of malaria using anti-CSP antibodies. Methods of determining efficacy of candidate vaccine compositions in development and testing of anti-malarial vaccines.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: July 20, 2021
    Assignees: KYMAB LIMITED, ATRECA, INC.
    Inventors: Qi Liang, Sean Matthew Carroll, Daniel Eric Emerling, Allan Bradley, Paul Kellam, {hacek over (S)}pela Binter, Simon James Watson
  • ANTI-MALARIAL ANTIBODIES THAT BIND CIRCUMSPOROZOITE PROTEIN
    Publication number: 20180362628
    Abstract: Antibodies that bind to the circumsporozoite protein (CSP) of Plasmodium falciparum. Use of such antibodies as anti-malarial agents, to confer protection against infection by malarial parasites such as P. falciparum by insect vector transmission. Diagnosis of malaria using anti-CSP antibodies. Methods of determining efficacy of candidate vaccine compositions in development and testing of anti-malarial vaccines.
    Type: Application
    Filed: May 11, 2018
    Publication date: December 20, 2018
    Applicants: KYMAB LIMITED, ATRECA, INC.
    Inventors: Qi Liang, Sean Matthew Carroll, Daniel Eric Emerling, Allan Bradley, Paul Kellam, Spela Binter, Simon James Watson
  • Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 10112926
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: October 30, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Publication number: 20180243297
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 26, 2018
    Publication date: August 30, 2018
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 10004732
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Benjamin Richard Bellenie, Graham Charles Bloomfield, Ian Bruce, Andrew James Culshaw, Edward Charles Hall, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
    Patent number: 9862711
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: January 9, 2018
    Assignee: NOVARTIS AG
    Inventors: Benjamin Richard Bellenie, Ian Bruce, Andrew James Culshaw, Gregory John Hollingworth, James Neef, Matthew Spendiff, Simon James Watson
  • AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170042889
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 16, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170037032
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 9, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Graham Charles BLOOMFIELD, Ian BRUCE, Andrew James CULSHAW, Edward Charles HALL, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
    Publication number: 20170029414
    Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 2, 2017
    Applicant: NOVARTIS AG
    Inventors: Benjamin Richard BELLENIE, Ian BRUCE, Andrew James CULSHAW, Gregory John HOLLINGWORTH, James NEEF, Matthew SPENDIFF, Simon James WATSON
  • Pyrrolopyridine derivatives and their use as CRTH2 antagonists
    Patent number: 9169251
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: October 27, 2015
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 9115087
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: August 25, 2015
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson
  • PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS
    Publication number: 20140309254
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 16, 2014
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • ORGANIC COMPOUNDS
    Publication number: 20140213594
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: April 1, 2014
    Publication date: July 31, 2014
    Applicant: NOVARTIS AG
    Inventors: Urs BAETTIG, Anne-Marie D'SOUZA, Peter HUNT, Neil John PRESS, Simon James WATSON
  • Pyrrolopyridine derivatives and their use as CRTH2 antagonists
    Patent number: 8791256
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: July 29, 2014
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 8722925
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 13, 2014
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'souza, Peter Hunt, Neil John Press, Simon James Watson
  • PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS
    Publication number: 20130267518
    Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Application
    Filed: June 5, 2013
    Publication date: October 10, 2013
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katherine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Organic compounds
    Patent number: 8470848
    Abstract: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: June 25, 2013
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • Pyrrolopyridine derivatives and their use as CRTH2 antagonists
    Patent number: 8455645
    Abstract: There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: June 4, 2013
    Assignee: Novartis AG
    Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
  • ORGANIC COMPOUNDS
    Publication number: 20130005735
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 3, 2013
    Inventors: Urs Baettig, Anne-Marie D'souza, Peter Hunt, Neil John Press, Simon James Watson
  • Squaramide derivatives as CXCR2 antagonist
    Patent number: 8329754
    Abstract: The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: December 11, 2012
    Assignee: Novartis AG
    Inventors: Urs Baettig, Anne-Marie D'Souza, Peter Hunt, Neil John Press, Simon James Watson